Table 2.
Respondent familiarity with RA guidelines
| (n = 125) | ||
|---|---|---|
| N | % | |
| (A) How familiar are you with the following guidelines for the management of RA? | ||
| 2012 update of the 2008 ACR recommendations for the use of DMARDs and biologic agents in the treatment of RA | ||
| Very familiar | 73 | 58 |
| Somewhat familiar | 47 | 38 |
| Not familiar | 5 | 4 |
| 2010 RA classification criteria: an ACR/EULAR collaborative initiative | ||
| Very familiar | 68 | 54 |
| Somewhat familiar | 53 | 42 |
| Not familiar | 4 | 3 |
| EULAR recommendations for the management of RA with synthetic and biological DMARDs (2010) | ||
| Very familiar | 49 | 39 |
| Somewhat familiar | 60 | 48 |
| Not familiar | 16 | 13 |
| (B) Please specify your agreement with the following statements | ||
| The classification criteria for RA include joint involvement, serology (rheumatoid factor and anti-citrullinated protein antibody), acute phase reactants (CRP and ESR), and duration of symptoms | ||
| Agree | 118 | 94 |
| Disagree | 7 | 6 |
| Patients with early RA who have moderate or high disease activity and poor prognostic features should be started on DMARD combination therapy (including double and triple therapy) | ||
| Agree | 96 | 77 |
| Disagree | 29 | 23 |
| If a patient is in persistent remission after having tapered glucocorticoids, one can consider tapering biological DMARDs, especially if this treatment is combined with a synthetic DMARD | ||
| Agree | 86 | 69 |
| Disagree | 39 | 31 |
ACR American College of Rheumatology, CRP C-reactive protein, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, EULAR European League Against Rheumatism, RA rheumatoid arthritis